



PART I	Particulars	Standalone				Consolidated			
		Unaudited Current Quarter Ended 30.06.2015	Unaudited Previous Quarter ended 31.03.2015	Unaudited Corresponding Quarter Ended 30.06.2014	Audited Previous Year Ended 31.03.2015	Unaudited Current Quarter Ended 30.06.2015	Unaudited Previous Quarter ended 31.03.2015	Unaudited Corresponding Quarter Ended 30.06.2014	Audited Previous Year Ended 31.03.2015
1	Income from operations (a) Net sales/income from operations (Net of excise duty) (b) Other operating income Total income from operations (net)	251.77 5.35 257.72	387.78 45.31 433.09	285.58 11.07 296.65	1,585.55 77.56 1,663.11	1,827.71 5.95 1,833.66	2,119.23 11.07 2,130.30	10,274.63 81.41 10,356.04	
2	Expenses (a) Cost of materials consumed (b) Purchases of stock-in-trade (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (d) Employee benefits expense (e) Depreciation and amortisation expense (f) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	116.56 7.81 21.62 33.17 14.49 63.26	142.74 98.53 (6.63) 68.96 21.03 84.89	179.63 57.12 62.19 20.15 60.69	722.45 153.52 155.26 284.33 79.85 301.67	796.17 7.81 45.72 170.70 59.67 333.21	1,237.64 99.53 (47.73) 191.00 94.05 365.45	6,326.90 151.52 210.72 771.76 299.32 1,609.92	
	Total expenses	289.91 (2.19)	410.52 (63.14)	379.79 (63.14)	1,697.08 (33.97)	1,425.38 208.28	2,622.23 108.35	9372.13 983.91	
3	Profit / (Loss) from operations before other income, finance costs and exceptional items(1-2)	(2.19)	77.57	(83.14)	(33.97)	208.28	198.19	983.91	
4	Other income								
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	(2.19)	77.57	(83.14)	(33.97)	208.28	198.19	983.91	
6	Finance costs	30.27	37.19	61.88	141.44	122.79	108.35	435.77	
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 ± 6)	(37.46)	(14.67)	(125.02)	(175.41)	85.49	89.84	544.14	
8	Exceptional items								
9	Profit / (Loss) from ordinary activities before tax (7 ± 8)	(37.46)	(14.67)	(125.02)	(175.41)	85.49	89.84	544.14	



PART II		Current Quarter Ended 30.06.2015	Previous Quarter ended 31.03.2015	Corresponding Quarter Ended 30.06.2014	Previous Year Ended 31.03.2015
<b>A</b>	<b>PARTICULARS OF SHAREHOLDING</b>				
1	Public shareholding - Number of shares - Percentage of shareholding	3,217,850 37.84	3,254,850 38.39	3,294,950 38.74	3,254,850 38.39
2	Promoter and Promoter Group Shareholding a) Pledged / Encumbered - Number of shares - Percentage of shares (as a % of the total shareholding of promoter and promoter group) - Percentage of shares (as a % of the total share capital of the company) b) Non-encumbered - Number of shares - Percentage of shares (as a % of the total shareholding of promoter and promoter group) - Percentage of shares (as a % of the total share capital of the company)	781,488 15.00 9.19	781,488 14.91 9.19	781,488 15.00 9.19	781,488 14.91 9.19
		4,505,528 85.00 52.98	4,453,528 85.00 52.42	4,428,428 85.00 52.07	4,458,528 85.00 52.42

PARTICULARS		30.06.2015
<b>B</b>	<b>INVESTOR COMPLAINTS</b>	
	Pending at the beginning of the quarter	NIL
	Received during the quarter	NIL
	Disposed of during the quarter	NIL
	Remaining unresolved at the end of the quarter	NIL



**Notes:**

1	The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 14, 2015
2	The Statutory Auditors have carried out a 'Limited Review' of the financial results for the quarter ended 30th June, 2015
3	The Company has opted to submit Standalone as well as Consolidated financial statements. The Consolidated financial results comprise the results of Parnax Lab Limited and One Subsidiary Company
4	Pursuant to approval of Registrar of Companies, Mumbai, the name of the Company is changed to Parnax Lab Ltd w.e.f April 2, 2012
5	The Company is dealing into one segment : Dealing in Pharmaceutical Formulations
6	Figures pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.
7	The provision for income tax and deferred tax shall be made at the year end.
8	EPS for quarter ended is on non annualised basis.
9	The Company is dealing into one segment : Dealing in Pharmaceutical Formulations

Date: 14.08.2015  
Place: Mumbai

For Parnax Lab Limited



Whole  
Time Director & CEO  
Din No -00440980



**LIMITED REVIEW REPORT**

To,  
The Board of Directors  
Parnax Lab Limited

We have reviewed the accompanying statement of unaudited financial results of Parnax Lab Limited for the quarter ended June 30, 2015, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group' Shareholding which have been traced from disclosures made by the Management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors at their meeting held on August 14, 2015. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ladha Singhal & Associates  
Chartered Accountants  
Firm's Registration No : 120241W

*Vinod Ladha*  
Vinod Ladha  
(Partner)  
M. No. : 104151  
Place: Mumbai  
Date: August 14, 2015

